Abstract:Clinically evident high-altitude pulmonary edema (HAPE) is characterized by severe cyanosis, dyspnea, cough, and difficulty with physical exertion. This usually occurs within 1-2 days of ascent often with the additional stresses of any exercise and hypoventilation of sleep. The earliest events in evolving HAPE progress through clinically silent and then minimally recognized problems. The most important of these events involves an exaggerated elevation of pulmonary artery (PA) pressure in response to the ambient hypoxia. Hypoxic pulmonary vasoconstriction (HPV) is a rapid response with several phases. The first phase in both resistance arterioles and venules occurs within 5-10 min. This is followed by a second phase that further raises PA pressure by another 100% over the next 2-8 h. Combined with vasoconstriction and likely an unevenness in the regional strength of HPV, pressures in some microvascular regions with lesser arterial constriction rise to a level that initiates greater filtration of fluid into the interstitium. As pressures continue to rise local lymphatic clearance rates are exceeded and interstitial fluid begins to accumulate. Beyond elevation of transmural pressure gradients there is a dynamic noninjurious relaxation of microvascular and epithelial cell-cell contacts and an increase in transcellular vesicular transport which accelerate leakage. At some point with further pressure elevation, damage occurs with breaks of the barrier and bleeding into the alveolar space, a late-stage situation termed capillary stress failure. Earlier before there is fluid accumulation, alveolar hypoxia and hyperventilation-induced hypocapnia reduce the capacity of the alveolar epithelium to reabsorb sodium and water back into the interstitial space. More modest ascent which slows the rate of rise in PA pressure and allows for adaptive remodeling of the microvasculature, drugs which lower PA pressure, and those that can enhance fluid reabsorption will all forestall the deleterious early rise of microvascular pressures and diminished active alveolar fluid reabsorption that precede and underlie the development of HAPE.

Prevention and Treatment of Acute High Pulmonary Edema: Research Progress

Research advances in pathogenesis and prophylactic measures of acute high altitude illness

Medical Treatment of High Altitude Pulmonary Edema

The use of noninvasive ventilation in the treatment of acute cardiogenic pulmonary edema

Effect of furosemide in the treatment of high-altitude pulmonary edema

Physiopathology of High-Altitude Pulmonary Edema.

Progress in diagnosis and treatment of high-altitude acute respiratory distress syndrome

Clinical and Pathophysiological Features of High-altitude Pulmonary Edema in the Japanese Population: A Review of Studies on High-altitude Pulmonary Edema in Japan

Evaluation and Management of the Individual with Recurrent High Altitude Pulmonary Edema

[Research progress of traditional Chinese and Western medicine non-pharmacological prevention strategies for acute high altitude disease]

Clinical research and treatment strategy of acute pulmonary edema

Advanced treatment strategies for high-altitude pulmonary hypertension employing natural medicines: A review

Expression of Aquaporin-1 and Aquaporin-5 in a Rat Model of High-Altitude Pulmonary Edema and the Effect of Hyperbaric Oxygen Exposure

Genetics of High-Altitude Pulmonary Edema

New Insights of Aquaporin 5 in the Pathogenesis of High Altitude Pulmonary Edema

An update on environment-induced pulmonary edema - "When the lungs leak under water and in thin air"

Transcriptomic Profiling Reveals Gene Expression Kinetics in Patients with Hypoxia and High Altitude Pulmonary Edema.

Research Progress of Patent Foramen Ovale and High-Altitude Pulmonary Edema

High-altitude Cerebral Edema and High-altitude Pulmonary Edema Diagnosed in the Desert: A Case Report

Early hours in the development of high-altitude pulmonary edema: time course and mechanisms

Exercise performance reduction and preventive measures in highland sports